{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:03:23Z","timestamp":1790705003906,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.ando.2008.02.003","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:07:36Z","timestamp":1208596056000},"page":"174-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cancers anaplasiques de la thyro\u00efde"],"prefix":"10.1016","volume":"69","author":[{"given":"J.-L.","family":"Wemeau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Do Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2008.02.003_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0","article-title":"Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program (1973\u20131991)","volume":"79","author":"Gilliland","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib2","series-title":"Anaplastic thyroid cancinoma","article-title":"Thyroid tumors","author":"Schlumberger","year":"2003"},{"key":"10.1016\/j.ando.2008.02.003_bib3","first-page":"159","article-title":"Anaplastic (sarcomatoid) carcinoma of the thyroid gland","volume":"10","author":"Lampertico","year":"1993","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.ando.2008.02.003_bib4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/1097-0142(195711\/12)10:6<1119::AID-CNCR2820100607>3.0.CO;2-M","article-title":"The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth","volume":"10","author":"Crile","year":"1957","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A","article-title":"Anaplastic carcinoma of the thyroid. A clinicopathologic study of 121 cases","volume":"66","author":"Venkatesh","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib6","first-page":"47","article-title":"Thyroid cancer: pathologic and natural history","volume":"73","author":"Williams","year":"1980","journal-title":"Cancer Res"},{"key":"10.1016\/j.ando.2008.02.003_bib7","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2008.02.003_bib8","first-page":"159","article-title":"High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis","volume":"4","author":"Lemoine","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.ando.2008.02.003_bib9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1172\/JCI116385","article-title":"Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland","volume":"91","author":"Donghi","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2008.02.003_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1172\/JCI116168","article-title":"High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas","volume":"91","author":"Fagin","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2008.02.003_bib11","first-page":"1369","article-title":"Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland","volume":"52","author":"Ito","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.ando.2008.02.003_bib12","first-page":"2029","article-title":"A mutated p53 gene alters thyroid cell differentiation","volume":"11","author":"Battista","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.ando.2008.02.003_bib13","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/sj.bjc.6603764","article-title":"BRAF V600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas","volume":"96","author":"Takano","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1067\/msy.2001.118266","article-title":"Anaplastic thyroid carcinoma: a 50-year experience at a single institution","volume":"130","author":"McIver","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2008.02.003_bib15","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/00001622-200301000-00012","article-title":"Anaplastic thyroid cancer","volume":"15","author":"Pasieka","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ando.2008.02.003_bib16","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2265.2002.01495.x","article-title":"Anaplastic pseudothyroiditis","volume":"56","author":"Basaria","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ando.2008.02.003_bib17","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/sj.bjc.6600361","article-title":"Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery","volume":"86","author":"Tennvall","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib18","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00423-004-0524-5","article-title":"Prognostic factors in anaplastic carcinoma of the thyroid-a multivariate survival analysis of 188 patients","volume":"390","author":"Besic","year":"2005","journal-title":"Langenbecks Arch Surg"},{"key":"10.1016\/j.ando.2008.02.003_bib19","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1159\/000334007","article-title":"Anaplastic thyroid carcinoma in fine needle aspirates","volume":"40","author":"Us-Krasovec","year":"1996","journal-title":"Acta Cytol"},{"key":"10.1016\/j.ando.2008.02.003_bib20","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1023\/A:1008322002520","article-title":"Anaplastic thyroid carcinoma: current diagnosis and treatment","volume":"11","author":"Giuffrida","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ando.2008.02.003_bib21","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1023\/A:1010079031162","article-title":"Expression patterns of cellular growth-controlling genes in non-medullary thyroid cancer: basic aspects","volume":"1","author":"Sarlis","year":"2000","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.ando.2008.02.003_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s002680020166","article-title":"Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid","volume":"25","author":"Sugitani","year":"2001","journal-title":"World J Surg"},{"key":"10.1016\/j.ando.2008.02.003_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1530\/EJE-06-0677","article-title":"Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years","volume":"156","author":"Brignardello","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2008.02.003_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/ajcp\/83.2.135","article-title":"Anaplastic thyroid carcinoma. A study of 70 cases","volume":"83","author":"Carcangiu","year":"1985","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ando.2008.02.003_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/(SICI)1097-0347(199601\/02)18:1<36::AID-HED5>3.0.CO;2-#","article-title":"Treatment of 37 patients with anaplastic carcinoma of the thyroid","volume":"18","author":"Kobayashi","year":"1996","journal-title":"Head Neck"},{"key":"10.1016\/j.ando.2008.02.003_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/ejso.2000.1098","article-title":"Effect of primary treatment on survival in anaplastic thyroid carcinoma","volume":"27","author":"Besic","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ando.2008.02.003_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF03348135","article-title":"Chemotherapy of thyroid carcinoma","volume":"10","author":"Ahuja","year":"1987","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2008.02.003_bib28","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E","article-title":"A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma","volume":"56","author":"Shimaoka","year":"1985","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib29","first-page":"405","article-title":"Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial","volume":"70","author":"Williams","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"10.1016\/j.ando.2008.02.003_bib30","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF03346846","article-title":"Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer","volume":"14","author":"De Besi","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ando.2008.02.003_bib31","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3835(97)04742-3","article-title":"Lack of a point mutation of human DNA topoisomerase II in multidrug-resistant anaplastic thyroid carcinoma cell lines","volume":"116","author":"Satake","year":"1997","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ando.2008.02.003_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/thy.2000.10.587","article-title":"Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group","volume":"10","author":"Ain","year":"2000","journal-title":"Thyroid"},{"key":"10.1016\/j.ando.2008.02.003_bib33","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1002\/1097-0142(19940815)74:4<1348::AID-CNCR2820740427>3.0.CO;2-D","article-title":"Combined doxorubicin, hyperfractionated radiotherapy, and surgery in anaplastic thyroid carcinoma. Report on two protocols. The Swedish Anaplastic Thyroid Cancer Group","volume":"74","author":"Tennvall","year":"1994","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib34","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.ijrobp.2004.05.032","article-title":"Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy","volume":"60","author":"De Crevoisier","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ando.2008.02.003_bib35","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1245\/aso.2002.9.1.57","article-title":"The effect of surgery and radiotherapy on outcome of anaplastic thyroid carcinoma","volume":"9","author":"Pierie","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ando.2008.02.003_bib36","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","article-title":"Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival","volume":"91","author":"Haigh","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib37","first-page":"728","article-title":"Does surgery improve the survival of patients with advanced anaplastic thyroid carcinoma?","volume":"118","author":"Lu","year":"1998","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ando.2008.02.003_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1067\/msy.2002.119936","article-title":"The important role of operations in the management of anaplastic thyroid carcinoma","volume":"131","author":"Sugino","year":"2002","journal-title":"Surgery"},{"key":"10.1016\/j.ando.2008.02.003_bib39","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1002\/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO;2-1","article-title":"Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy","volume":"60","author":"Kim","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1097-0142(19871001)60:7<1428::AID-CNCR2820600703>3.0.CO;2-P","article-title":"Multimodality treatment in anaplastic giant cell thyroid carcinoma","volume":"60","author":"Tallroth","year":"1987","journal-title":"Cancer"},{"key":"10.1016\/j.ando.2008.02.003_bib41","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1210\/jcem.85.11.6941","article-title":"Adenovirus-mediated tumor suppressor p53 gene therapy for anaplastic thyroid carcinoma in vitro and in vivo","volume":"85","author":"Nagayama","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2008.02.003_bib42","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1210\/jc.2002-020877","article-title":"A histone deacetylase inhibitor enhances killing of undifferentiated thyroid carcinoma cells by p53 gene therapy","volume":"87","author":"Imanishi","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2008.02.003_bib43","first-page":"1769","article-title":"Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma","volume":"86","author":"Xu","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2008.02.003_bib44","first-page":"3408","article-title":"A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati","year":"2002","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.ando.2008.02.003_bib45","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/jnci\/92.7.520","article-title":"Antiangiogenesis drugs target specific cancers, mechanisms","volume":"92","author":"Randal","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ando.2008.02.003_bib46","doi-asserted-by":"crossref","first-page":"8594","DOI":"10.1158\/1078-0432.CCR-04-0690","article-title":"Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer","volume":"10","author":"Schiff","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ando.2008.02.003_bib47","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00280-006-0286-6","article-title":"A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors","volume":"59","author":"Fury","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ando.2008.02.003_bib48","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s00280-006-0185-x","article-title":"Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells","volume":"58","author":"Kurebayashi","year":"2006","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426608000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426608000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T22:42:39Z","timestamp":1757716959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426608000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S0003426608000371"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2008.02.003","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancers anaplasiques de la thyro\u00efde","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2008.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}